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Abstract 
OBJECTIVE: The purpose of the study reported here was to evaluate pharmacokinetics 
of cefazolin in dogs receiving a single IV injection of cefazolin (22 mg/kg) and dogs receiving 
simultaneous IV and IM injections of cefazolin (total dose, 44 mg/kg). 
 
METHODS: Twelve purpose-bred Beagles (6/group) were assigned to receive a single 
injection of cefazolin (22 mg/kg, IV) or simultaneous injections (22 mg/kg, IV, and 22 mg/kg, 
IM). Interstitial fluid was collected over a 5-hour period using ultrafiltration probes for 
pharmacokinetic analysis. 
 
RESULTS: Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 
hours after injection was 39.6, 29.1, 21.1, 10.3, 6.4, and 2.7 g/mL, respectively, for the IV 
group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 g/mL, respectively, for the IV + IM group. The 
mean area under the concentration-time curve extrapolated to infinity, maximum concentration, 
half life and time to the maximum concentration was 74.99 and 154.16 h•g/mL, 37.3 and 51.5 
g/mL, 0.96 and 1.11 hours, 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.  
 
CONCLUSIONS AND CLINICAL RELEVANCE: Cefazolin concentrations in 
interstitial fluid of dogs were maintained at > 4 g/mL for 4 hours after a single IV injection and 
for 5 hours after simultaneous IV and IM injections. Based on these results, simultaneous 
administration of cefazolin IV + IM 30 to 60 minutes before surgery should provide interstitial 
fluid concentrations effective against the most common commensal organisms (Staphylococcus 
spp and Streptococcus spp) on the skin of dogs for surgical procedures lasting ≤ 4 hours. 
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CHAPTER 1 – USE OF ANTIMICROBIAL PROPHYLAXIS 
DURING SURGERY  
The use of peri-operative antibiotics to decrease the incidence of surgical-site infections 
(SSI) has been well established.1-6 Antimicrobials are recommended in procedures associated 
with high risk of infection or when postoperative infection would have catastrophic 
consequences on the outcome of surgery.3, 7-9 In humans and animals, SSI can be a devastating 
complication, prolong the length of hospital stay and dramatically increase medical costs.5, 10, 11 
There are some important concepts associated with the use of antimicrobial prophylaxis and they 
will be discussed in this report.  
 
 Surgical Site Infections 
There is conflicting evidence of the efficacy of prophylactic antimicrobials in veterinary 
medicine, with some studies12 showing no effect and other studies showing a decrease in the 
incidence of SSI for routine clean surgical procedures. 3, 13 A randomized blinded prospective 
controlled study showed that the infection rate for control dogs was significantly higher (15.7%) 
than the rate for dogs treated with peri-operative antimicrobials (3.8%).3 In another study, 347 of 
365 dogs (95.3%) that underwent orthopedic surgery received peri-operative antibiotics. Five of 
347 (0.01%) developed SSI, whereas 3 of 16 (18.7%) that did not receive peri-operative 
antibiotic developed SSI.13 Other studies have shown an overall infection rate between 5.9% and 
8.9% for a variety of clean and clean-contaminated procedures with a conclusion that 
prophylaxis was not required for these procedures.14-16 
 
Bacterial drug resistance (including multi-drug resistant bacteria), increased risk of 
hospital-acquired infection, and increased cost of the medical care are possible consequences of 
inappropriate or indiscriminate use of antimicrobials.1, 15, 17-19 A study in humans showed that 
antimicrobial prophylaxis was often not consistent with local or national guidelines; redosing 
schedule was followed at an appropriate time only in 40% of the cases but improved to 68% with 
an automatic reminder system.20 A different study in humans from a tertiary teaching hospital 
found that only 3 per cent of the procedures received an appropriate medication, dose, duration 
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and redose timing according to the hospital guidelines.19 Similarly, dogs undergoing orthopedic 
surgery showed discrepancies between standard recommendations and the antimicrobial 
prophylaxis used. Sixteen per cent of the dogs did not receive the drug within 60 minutes of 
surgery, 19% received unnecessary repeated doses and 49% received additional doses at an 
incorrect time.15  
 
Multiple studies have shown that the timing of antibiotic administration and redosing 
schedule are not always performed according to the institution guidelines. One study found that 
78% of dogs received the first antimicrobial dose before surgery; out of these dogs 84% received 
the dose within 60 minutes of the first incision. Twelve percent of dogs were initially treated 
during surgery, 10 to 165 minutes after the first incision. If a guideline of repeated administration 
every 90 minutes after the first administration until closure of the surgical-site was used, 51% 
dogs received the required intraoperative administration, and 19% of dogs that did not require 
intraoperative dosing were treated.12 A more recent study showed a redosing incidence of 93.5%, 
which they considered excellent; however, 28.4% of dogs received antimicrobials late, with the 
dose being administered more than 30 minutes late in 28% of those dogs.21 
 
 Antibiotic Selection 
The antibiotic selected for prophylactic use must be effective against the pathogen most 
likely to cause postoperative wound infection.3, 7, 8 Antibiotics with efficacy against commonly 
encountered pathogens, such as Staphylococcus spp., Streptococcus spp. and sometimes 
Escherichia coli, are usually recommended in veterinary medicine based on the location of the 
surgery. In order for antimicrobial prophylaxis to be effective, it must be present at the surgical-
site at an adequate concentration before the time of contamination and throughout the surgical 
procedure.6-8, 22, 23  
Cephalosporins are effective antimicrobials, well tolerated, and obtain targeted serum and 
tissue concentrations.9 Cefazolin has been recommended as the ideal prophylactic antibiotic for 
surgery in dogs and has become one of the most common antimicrobials for peri-operative use 
because of its spectrum, low incidence of adverse effects, and low cost.3, 7, 8, 24 The beta-lactam 
antimicrobials (penicillins and cephalosporins) are time-dependent, meaning that efficacy is 
correlated with the time that drug concentration remains above the minimum inhibitory 
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concentration (MIC) for a particular pathogen.7, 25 Based on pharmacokinetic studies it has been 
recommended for time-dependent antimicrobials such as beta-lactams to be redosed 
intraoperatively every 2 half-lives in order to maintain targeted plasma concentrations.7, 8, 12, 24 
 
Cefazolin is not appreciably absorbed after oral administration and must be given 
parenterally to achieve therapeutic serum levels. Absorbed drug is excreted unchanged by the 
kidneys into the urine. Elimination half-lives may be significantly prolonged in patients with 
severely diminished renal function. In dogs, peak levels occur in about 30 minutes after IM 
administration. The apparent volume of distribution at steady state is 700 mL/kg, total body 
clearance of 10.4 mL/min/kg with a serum elimination half-life of 48 minutes. Approximately 
64% of the clearance can be attributed to renal tubular secretion. The drug is approximately 16–
28% bound to plasma proteins in dogs.26 
 
 Antibiotic Interstitial Fluid Concentration 
Protein binding is a major factor in the tissue distribution of a drug.22 In order to predict 
antimicrobial activity, it is important to know the concentration of the protein-unbound 
antimicrobial at the site of bacterial contamination (surgical-site). A previous study has 
suggested that the concentration of cefazolin in the ISF is similar to plasma due to rapid 
equilibration of cefazolin between serum and soft tissues in the surgical wound.8 To date, only 
two studies have measured and compared the concentration of cefazolin in the surgical-site to 
serum by obtaining muscle biopsies and determining the antibiotic concentration by the use of a 
modified agar plate diffusion technique.7,23 However, tissue concentrations may underestimate 
true surgical site concentrations as the interstitial fluid is diluted with the intracellular fluid. One 
alternative to determine the antibiotic concentration in the interstitial fluid is the utilization of 
tissue cages and by ultrafiltration. 
 
The concentration of antibacterial agents in the interstitial tissue fluid has been studied in an 
experimental model using implanted perforated Silastic capsules (tissue cages). The lining within 
the cage contains young fibroblasts, many capillaries, and obvious tissue spaces. The rate of 
diffusion into and out of the cage fluid of small molecules, such as sodium, is rapid, whereas for 
larger molecules, such as albumin, it is slower.27-29 These tissue cages, however, need to be 
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implanted 4 weeks prior to the sampling collection to allow ingrowth of cells into the cages and 
production of interstitial fluid. 
 
On the other hand, some researchers have used ultrafiltration. Ultrafiltration provides a means 
for collecting protein-unbound cefazolin in the ISF by use of an implanted semipermeable 
membrane in the tissue. Previous studies 30-32 have shown that an ultrafiltration device is a 
reliable and convenient method for collecting ISF samples from tissues in dogs. This device has 
become the preferred method for collecting ISF, rather than collection of tissue biopsy specimens 
or use of tissue cages, because of anatomic and physiologic relevance, lack of contamination 
from intracellular content, ease of insertion, the ability to collect serial samples with the same 
device, and monitoring of drug distribution in unrestrained animals. Furthermore, the 
ultrafiltration device provides a convenient method for continuous sample collection without 
residual wounds or lesions after removal of the ultrafiltration probes.22 
 
 Pharmacokinetic Analysis 
Reversed-phase gradient high performance liquid chromatography (HPLC) has become 
the preferred method for drug discovery and drug metabolism studies.33 HPLC is a technique 
in analytical chemistry used to separate, identify, and quantify each component in a mixture. It 
relies on pumps to pass a pressurized liquid solvent, containing the sample mixture, through a 
column filled with a solid adsorbent material. Each component in the sample interacts slightly 
differently with the adsorbent material, causing different flow rates for the different components 
and leading to the separation of the components as they flow out the column. The coupling of a 
mass spectrometer with liquid chromatography, and the advent of atmospheric pressure 
ionization interfaces, have resulted in significant improvements in sensitivity and specificity of 
analytical assays.33 
Chromatography can be described as a mass transfer process involving adsorption. HPLC 
relies on a column filled with adsorbent. The active component of the column, the adsorbent, is 
typically a granular material made of solid particles 2–50 micrometers in size. The components 
of the sample mixture are separated from each other due to their different degrees of interaction 
with the adsorbent particles. The pressurized liquid is typically a mixture of solvents and is 
referred to as a "mobile phase". Its composition and temperature play a major role in the 
5 
separation process by influencing the interactions taking place between sample components and 
adsorbent. The concentrations of cefazolin in interstitial fluid can be determined by use of ultra-
performance liquid chromatography coupled with ultraviolet detection (UPLC-UV). 
6 
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 Abstract 
OBJECTIVE 
To evaluate pharmacokinetics of cefazolin after a single IV injection of cefazolin (22 
mg/kg) and after simultaneous IV and IM injections of cefazolin (total dose, 44 mg/kg) to dogs. 
 
ANIMALS  
12 adult Beagles. 
 
PROCEDURES 
Dogs (6/group) were assigned to receive a single injection of cefazolin (22 mg/kg, IV) or 
simultaneous injections (22 mg/kg, IV, and 22 mg/kg, IM). Interstitial fluid was collected over a 
5-hour period using ultrafiltration probes for pharmacokinetic analysis. 
 
RESULTS  
Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after 
injection was 39.6, 29.1, 21.1, 10.3, 6.4, and 2.7 g/mL, respectively, for the IV group and 38.3, 
53.3, 46.4, 31.7, 19.1, and 8.9 g/mL, respectively, for the IV + IM group. The mean area under 
the concentration-time curve extrapolated to infinity, maximum concentration, half life and time 
to the maximum concentration was 74.99 and 154.16 h•g/mL, 37.3 and 51.5 g/mL, 0.96 and 
1.11 hours, 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.  
 
CONCLUSIONS AND CLINICAL RELEVANCE  
Cefazolin concentrations in interstitial fluid of dogs were maintained at > 4 g/mL for 4 
hours after a single IV injection and for 5 hours after simultaneous IV and IM injections. Based 
on these results, simultaneous administration of cefazolin IV + IM 30 to 60 minutes before 
surgery should provide interstitial fluid concentrations effective against the most common 
commensal organisms (Staphylococcus spp and Streptococcus spp) on the skin of dogs for 
surgical procedures lasting ≤ 4 hours. 
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 Introduction 
It has been clearly established that perioperative administration of antimicrobials can 
decrease the incidence of SSIs.1–6 Antimicrobials are recommended for procedures associated 
with high risk of infection or when postoperative infection would have catastrophic 
consequences on the outcome of surgery.3,7–9 In humans and other animals, SSI can be a 
devastating complication, prolong the duration of hospital stay, and dramatically increase 
medical costs.5,10,11 There is conflicting evidence about the efficacy of prophylactic 
administration of antimicrobials in veterinary medicine; one investigator detected no effect,12 
whereas other investigators  detected a decrease in the incidence of SSI for routine clean surgical 
procedures.3,13 In a randomized blinded prospective controlled study,3 the infection rate for 
control dogs (15.7%) was significantly higher than the rate for dogs treated perioperatively with 
antimicrobials (3.8%). In another study,13 347 of 365 (95.3%) dogs that underwent orthopedic 
surgery received antimicrobials perioperatively. Only 5 of those 347 (0.01%) dogs developed 
SSI, whereas 3 of 16 (18.7%) dogs that did not receive antimicrobials perioperatively developed 
SSI. Investigators of other studies14–16 have found an overall infection rate between 5.9% and 
8.9% for a variety of clean and clean-contaminated procedures, and they have concluded that 
prophylactic antimicrobial administration was not required for these procedures. 
 
Antimicrobial-resistant bacteria (including multidrug resistant bacteria), increased risk of 
hospital-acquired infection, and increased cost of medical care are possible consequences of 
inappropriate or indiscriminate use of antimicrobials.1,15,17-19 Current guidelines in human 
medicine include use of antimicrobials only in clean-contaminated, contaminated, or dirty 
procedures; administration of the first dose of antimicrobial 1 hour before the first incision; 
readministration of the antimicrobial during surgery if the procedure is still ongoing after 2 half-
lives of the drug have passed; restriction of treatment to the duration of surgery or for 24 hours, 
except in certain situations (i.e., gross contamination or preexisting infection); and avoiding use 
of newer broad-spectrum antimicrobials.12 In 1 study,20 prophylactic administration of 
antimicrobials to humans was often not consistent with local or national guidelines because a 
redosing schedule was followed at an appropriate time in only 40% of the patients, although this 
improved to 68% when an automatic reminder system was used. In another study19 of humans at 
a tertiary teaching hospital, an appropriate medication, dose, duration, and redosing schedule in 
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accordance with the hospital guidelines was used for only 3% of the patients. Similarly, there are 
discrepancies antimicrobial use and standard recommendations with regard to timing of 
administration before and during surgery, duration, and antimicrobial prophylaxis for dogs 
undergoing orthopedic surgery. In 1 study,15 16% of the dogs did not receive the antimicrobial 
within 60 minutes after surgery, 19% received unnecessary repeated doses of the antimicrobial, 
and 49% received additional doses of the antimicrobial at an incorrect time.  
 
The antimicrobial selected for prophylactic use must be effective against the pathogen or 
pathogens most likely to cause postoperative wound infection.3,7,8 Antimicrobials with efficacy 
against commonly encountered pathogens, such as Staphylococcus spp, Streptococcus spp, and 
sometimes Escherichia coli, are usually recommended for use in veterinary medicine on the 
basis of the surgery location. Cephalosporins are effective antimicrobials, are tolerated well, and 
achieve targeted serum and tissue concentrations.9 Cefazolin has been recommended as the ideal 
prophylactic antimicrobial for surgery in dogs and has become one of the antimicrobials most 
commonly used perioperatively because of its spectrum, low incidence of adverse effects, and 
low cost.3,7,8,21 For antimicrobial prophylaxis to be effective, an adequate concentration of the 
drug must be present at the surgical site before the time of contamination and throughout the 
surgical procedure.6–8,22,23 The -lactam antimicrobials (penicillins and cephalosporins) are time-
dependent drugs, which means that efficacy is correlated with the amount of time that drug 
concentration remain above the MIC for a particular pathogen.7,24 On the basis of results of 
pharmacokinetic studies,7,8,12,23 it has been recommended that time-dependent antimicrobials 
such as -lactams should be readministered every 2 half-lives during surgery to maintain 
targeted plasma concentrations. 
 
In a previous study,8 it was suggested that the concentration of cefazolin in the interstitial 
fluid is similar to the concentration in plasma owing to rapid equilibration of cefazolin between 
serum and soft tissues in a surgical wound. To our knowledge, the concentration of cefazolin in 
the surgical site has been measured and compared with serum concentrations (by obtaining 
muscle biopsy specimens and determining the antimicrobial concentration with a modified agar 
plate diffusion technique) in only 2 studies.7,22 However, tissue concentrations may 
underestimate true surgical site concentrations because the interstitial fluid is diluted with 
13 
intracellular fluid. An ultrafiltration probe has been used to obtain interstitial fluid in other 
studies.25–27 It has been found that this is a reliable, easily performed, and useful method for the 
evaluation of drug disposition in dogs, and it eliminates the need for collection of tissue samples 
or use of tissue cages to estimate concentrations in tissues.  
 
The purpose of the study reported here was to compare the cefazolin concentration in 
interstitial fluid obtained from dogs receiving a single IV injection of cefazolin and dogs 
receiving simultaneous IV and IM injections of cefazolin. We hypothesized that the 
concentration in the interstitial fluid would be higher and more prolonged in the group receiving 
simultaneous IV and IM injections, compared with results for the group receiving only an IV 
injection.  
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 Materials and Methods 
Animals  
Twelve purpose-bred Beagles (6 males and 6 females) were used in the study. All dogs 
were 1 year old and considered healthy; a physical examination, CBC, and serum biochemical 
profile were performed to verify health of the dogs. All dogs had an albumin concentration > 3.4 
g/dL (range, 3.4 to 4.2 g/dL). All dogs were allowed to acclimatize to the environment before 
initiation of the study. The study was reviewed and approved by the Institutional Animal Care 
and Use Committee at Kansas State University.  
 
Implant placement  
Dogs were sedated with dexmedetomidine hydrochloridea (15 g/kg, IV). An indwelling 
percutaneous catheter was placed in the jugular vein, and 2 ultrafiltration probesb were placed in 
the dorsum of each dog. The ultrafiltration probes contained 3 loops with a 12-cm 
semipermeable membrane. The semipermeable membrane in the loop consisted of pores that 
allowed water, electrolytes, and low-molecular-weight (< 30 KDa) molecules to diffuse across 
the membrane but excluded the passage of proteins, protein-bound drugs, and other high-
molecular-weight compounds. For insertion of the ultrafiltration probes, an area (2.5 cm on each 
side of the midline at the dorsal caudolateral aspect of the scapulae) was shaved and aseptically 
prepared. One of the insertion sites was infused with a solution of 2% lidocaine hydrochloridec 
(1 mg/kg), a stab incision was made through the skin with a No. 11 scalpel blade, and 
subcutaneous tissues were identified. An introducer needle was inserted in the stab incision, 
advanced cranially through the subcutaneous tissues for a distance of 10 cm, and exited through 
the skin; the ultrafiltration probe was then threaded through the needle from a cranial to caudal 
direction (Figure1) until the tip of the probe was flush with the tip of the introducer needle. The 
introducer needle containing the probe was then retracted 3 cm so that the 3 loops of the probe 
remained under the skin in the interstitial space and the nonpermeable portion of the probe 
remained external to the dog’s skin. The ultrafiltration probe was then secured to the skin with a 
non-absorbable nylon sutured by use of a finger-trap pattern. A vacuum-vial needlee was attached 
to the ultrafiltration probe tubing, and a collection tube was attached to that needle to apply 
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negative pressure on the probe system for collection of interstitial fluid through the 
semipermeable membrane. The probe insertion procedure then was repeated for the opposite 
side. After the ultrafiltration probes were inserted, sedation was reversed by administration of 
atipamezole hydrochloridef (2.4 mg/kg, IM). The initial collection tubes were allowed to remain 
in place for ≥ 18 hours to equilibrate the system before the initiation of the study. 
 
Experimental design 
Dogs were assigned to 2 groups (6 dogs/group) by use of randomizing software.g At 24 
hours after placement of the IV catheter and filtration probes, dogs of one group (IV group) 
received an injection of cefazolinh (22 mg/kg, IV) and dogs of the other group (IV + IM group) 
received simultaneous IV and IM injections of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM). 
 
Sample collection  
Interstitial fluid was collected in a microcentrifuge tubei inserted in a red top vacuum 
tubej before (time 0) and 1, 1.5, 2, 3, 4, and 5 hours after administration of cefazolin. Samples 
were immediately placed on ice. All samples subsequently were stored at –70° C until testing 
was performed. 
 
UPLC-UV drug analysis  
Concentrations of cefazolin in interstitial fluid were determined by use of UPLC-UVk at 
271 nm. The mobile phase consisted of 1.7% formic acid in deionized water (solution A) and 1% 
formic acid in acetonitrile (solution B). The mobile phase gradient started at 90% solution A, 
decreased to 30% solution A from 0.1 to 2 minutes, decreased to 14.2% solution A at 2.5 
minutes, and increased to 90% solution A at 2.51 minutes (total run time, 3.5 minutes). A C18 
columnl maintained at 40°C was used for separation. The sample tray was maintained at 4°C, 
and injection volume was 5 L. Interstitial fluid samples were injected directly into the UPLC-
UV without prior treatment. Standard curve and quality control samples were created with 
pooled canine interstitial fluid (linear range, 0.25 to 250 g/mL). Accuracy of the assay 
determined by use of 6 replicates each for concentrations of 0.25, 5, and 250 g/mL was 103%, 
104%, and 92% of the actual concentration, respectively. Coefficient of variation for the assay 
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determined by use of 6 replicates each for concentrations of 0.25, 5, and 250 g/mL was 8%, 
9%, and 6%, respectively. 
 
Statistical analysis  
Statistical analysis of the concentration-time curve was performed with a commercially 
available software package.m Data were tested for equality of variance, and values for individual 
time points (1, 1.5, 2, 3, 4, and 5 hours) were compared between the 2 groups by use of an 
independent group means test. Pharmacokinetic analysis of interstitial fluid concentrations was 
performed with noncompartmental methods by use of computer software.n Interstitial fluid 
pharmacokinetic parameters (AUCINF [determined by use of the linear trapezoidal method] and 
t1/2) were calculated for each dog, and descriptive statistics (geometric mean, minimum, and 
maximum values) were reported.28 Values for Cmax and tmax were determined directly from the 
data. Statistical analysis of pharmacokinetic data was conducted with computer softwareo by use 
of the Mann-Whitney rank sum test.29 Values were considered significant at P < 0.05 
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 Results 
The IV group initially consisted of 3 males and 3 females; however, 1 male was removed 
from the study because the dog removed the ultrafiltration devices before the initiation of the 
sample collection period. Thus, data were collected for 5 dogs in the IV group (mean body 
weight, 8.7 kg; range, 7.4 to 10.8 kg). The IV + IM group consisted of 3 males and 3 females 
(mean body weight, 9.7 kg; range, 8.7 to 10.7 kg).  
 
Mean concentrations of cefazolin in interstitial fluid were measured for both groups 
(Figure 2; Table 1). Mean, minimum, and maximum concentrations of cefazolin obtained for 
the IV (Figure 3) and IV + IM (Figure 4) groups were plotted. 
 
Comparing the mean cefazolin concentration in interstitial fluid between the IV and IV + 
IM groups revealed no significant difference at 1 hour (39.6 and 38.3 g/mL, respectively) and 
1.5 hours (29.1 and 53.3 g/mL, respectively). However, the mean cefazolin concentration in 
interstitial fluid was significantly lower in the IV group, compared with the concentration in the 
IV + IM group, at 2 (21.1 and 46.4 g/mL, respectively; P = 0.001), 3 (10.3 and 31.7 g/mL, 
respectively; P = 0.002), 4 (6.4 and 19.1 g/mL, respectively; P = 0.042), and 5 (2.7 and 8.9 
g/mL, respectively; P = 0.003) hours.  
 
Comparing the mean values for pharmacokinetic parameters between the IV and IV + IM 
groups revealed a significant (P = 0.004) difference in AUCINF (74.99 and 154.16 h•g/mL, 
respectively; Table 2). In addition, the AUCINF was dose related. There was no significant 
difference between the IV and IV + IM groups for Cmax (37.3 and 51.5 g/mL, respectively), 
t1/2 (0.96 and 1.11 hours, respectively), and Tmax (1.28 and 1.65 hours, respectively). 
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 Discussion 
On the basis of results of the present study, we accepted the hypothesis that doubling the 
dose of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM) adds 1 half-life to persistence of the drug. 
Although not significant, the half-life was approximately 15% (approx. 10 minutes) longer for 
the IV + IM group, compared with the expected half-life if the IV dose had been doubled. There 
is a slightly longer drug exposure with every half-life. This slight increase in exposure time may 
be explained by a slower absorption rate when the drug is administered IM. After achieving 
equilibrium between the serum and interstitial fluid as a result of the IV injection of cefazolin, 
and given the constant elimination rate and low protein-binding capacity of the drug, the IM 
injection would increase the number of unbound molecules of cefazolin available for distribution 
for a longer period because of the higher total dose. 
 
In the present study, we found that concentrations of cefazolin in interstitial fluid in all 
dogs were maintained above 4 g/mL for 4 hours after a single injection of cefazolin (22 mg/kg, 
IV) and for 5 hours after injections of cefazolin (22 mg/kg, IV, and 22 mg/k, IM; total dose, 44 
mg/kg). This concentration should provide antimicrobial activity against the most common 
methicillin-susceptible commensal organisms on the skin of dogs (Staphylococcus 
pseudintermedius and Streptococcus spp) for clean surgical procedures. On the basis of these 
results, cefazolin (22 mg/kg, IV, and 22 mg/kg, IM) administered 30 to 60 minutes before 
surgery for surgical procedures lasting ≤ 4 hours would achieve and maintain the desired 
interstitial fluid concentrations. Cefazolin (22 mg/kg, IV) administered 30 to 60 minutes before 
surgery would maintain the interstitial fluid concentrations above the MIC90 for dogs undergoing 
short (≤ 3 hours) surgical procedures. These recommendations were based on the lowest 
(minimum) cefazolin concentration, rather than on the mean concentration, to maintain targeted 
concentrations in all dogs in the present study to reduce the risk of developing an SSI. However 
further studies are needed to confirm clinical extrapolation of these data. In the event that 
surgical time exceeds the aforementioned durations, administration of another dose of cefazolin 
(22 mg/kg, IV, at 4 hours after initial IV administration and 22 mg/kg, IV, at 5 hours after the 
initial IV and IM administration of 44 mg/kg) should maintain targeted concentrations in the 
interstitial fluid. 
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Total drug exposure (AUCINF) was approximately twice as high after 44 mg/kg (IV + IM 
group; 145.16 h•g/mL), compared with the value after 22 mg/kg (IV group; 74.99 h•g/mL), 
which suggested a dose-relation phenomenon. Interstitial fluid Cmax was less proportional (51.5 
g/mL after 44 mg/kg and 37.3 g/kg after 22 mg/kg). The less-than-proportional Cmax most 
likely was attributable to a delay in Tmax caused by absorption of the IM portion of the dose. 
However because cephalosporins are concentration-dependent antimicrobials, the lower-than-
proportional Cmax for the IV + IM group would not be detrimental and could be beneficial for 
decreasing concentration-dependent adverse effects, compared with results after IV 
administration of 44 mg/kg. 
 
Protein binding is a major factor for tissue distribution of a drug.21 To predict 
antimicrobial activity, it is important to know the concentration of the protein-unbound 
antimicrobial at the site of bacterial contamination (surgical site). Ultrafiltration provides a 
means for collecting protein-unbound cefazolin in the interstitial fluid by implantation of a 
semipermeable membrane in the tissue. Investigators of other studies25–27 have found that an 
ultrafiltration device is a reliable and convenient method for collecting interstitial fluid samples 
from tissues in dogs. This device has become the preferred method for collecting interstitial 
fluid, rather than collecting tissue biopsy specimens or using tissue cages, because of anatomic 
and physiologic relevance, lack of contamination from intracellular content, ease of insertion, 
collection of serial samples with the same device, and monitoring drug distribution in 
unrestrained animals. Furthermore, the ultrafiltration device provides a convenient method for 
continuous sample collection without residual wounds or lesions after removal of the 
ultrafiltration probes.21 To our knowledge, the study reported here was the first in which an 
ultrafiltration probe was used to determine the cefazolin concentration in interstitial fluid. By use 
of this device, we were able to detect a biologically accurate concentration of cefazolin in what 
we anticipate will be equivalent to the tissue biophase or surgical site, rather than in serum, 
which is a critical factor for determining the efficacy of agents used for prophylaxis against 
SSIs.30  
 
Timing of antibiotic administration and redosing schedules are not always in accordance 
with institution guidelines. In 1 study,12 investigators found that 78% of dogs received the first 
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antimicrobial dose before surgery; however, only 84% of those dogs received the dose within 60 
minutes before the first incision. Twelve percent of dogs were initially treated during surgery (10 
to 165 minutes after the first incision).12 If a guideline of repeated administration every 90 
minutes after the first administration until closure of the surgical site were used, 51% of dogs 
received the required intraoperative administration, and 19% of dogs that did not require 
intraoperative administration were treated.12 In a more recent study,23 investigators found a 
redosing incidence of 93.5%, which they considered excellent; however, 28.4% of dogs received 
antimicrobials late, with the dose being administered more than 30 minutes late in 28% of those 
dogs. In the study reported here, administration of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM) 
before surgery results in antimicrobial concentrations that should be adequate against the most 
common skin contaminants for surgical procedures expected to last ≤ 4 hours, and a redosing 
schedule would not be necessary. 
 
The bacteria most commonly involved in SSIs in dogs and cats are commensal organisms 
on the skin (gram-positive cocci) and normal flora from the gastrointestinal and other tracts 
(predominantly gram-negative rods), depending on the surgical procedure.15,31 Historically, it has 
been recommended that time-dependent antimicrobials such as -lactams be readministered 
during surgery every 2 half-lives to maintain therapeutic concentrations during surgery.7,8,12,23 
Investigators of other studies have reported that the MIC90 is 0.25 to 2 g/mL for S 
pseudintermedius,7,32,33 4 g/mL for Streptococcus spp,32,33 and 16 g/mL for E coli.7,24 A more 
recent study34 of E coli revealed an MIC that inhibited 75% of isolates was 4 g/mL and the 
MIC90 was 128 g/mL. It should be considered that although isolates were collected from 33 
infection sites in that study,34 approximately 70% of the isolates were from the urinary tract, with 
the ear being a distant second (7.2% of isolates), and no other body system providing more than 
4% of isolates. These isolates may have been exposed to various courses of antimicrobials prior 
to isolation (i.e., recurrent urinary tract and otic infections) and may not be representative of 
bacteria that would typically be found in surgical patients.  
 
The present study had some limitations. We were unable to determine pharmacokinetic 
parameters of cefazolin in serum because of presumed contamination of the percutaneous 
catheter with cefazolin during IV administration (data not included). Even if the drug residual in 
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the catheter was 0.1%, it would have biased the data substantially. Injection of the cefazolin and 
collection of blood samples were through the same catheter; therefore, the measured 
concentration of the drug in serum was not accurate, especially at early time points. Although we 
did not determine the pharmacokinetic parameters of cefazolin in serum, this information can be 
obtained from other studies.2,7,22,30 Furthermore, the primary site of interest in the present study 
was interstitial fluid. The AUC for serum after administration of a dose of 40 mg/kg is 192.5 
h•g/mL (11,548 g•min/mL), and t1/2 is 1.26 hours (75.8 minutes).22 The AUC for serum after 
administration of a dose of 20 mg/kg is 135.9 h•g/mL (8,158 g•min/mL), and t1/2 is 0.91 hours 
(5.08 minutes).7 Investigators of another study30 found the AUC for serum after administration of 
a dose of 20 mg/kg is 82.5 h•g/mL, and t1/2 is 1.53 hours. In the present study, AUC for the 
interstitial fluid was 74.99 h•g/mL and t1/2 was 0.96 hours after IV administration of a dose of 
22 mg/kg and AUC was 154.16 h•g/mL and t1/2 was 1.11 hours after administration of a dose of 
44 mg/kg (22 mg/kg, IV, and 22 mg/kg, IM). These results indicated that exposure to cefazolin 
after administration was extremely similar in the interstitial fluid and serum, which would 
indicate good penetration of the antimicrobial into a surgical site. 
 
Purpose-bred research Beagles that were considered healthy were used in the present 
study. This may not have been representative of the general population because there are patient 
variations associated with breed and size that may alter pharmacokinetics of cefazolin. Patients 
with underlying conditions or metabolic diseases that may increase glomerular filtration rate may 
also have increased clearance of cefazolin.35  
 
Dogs in the present study were not anesthetized and not subjected to surgical conditions. 
Some operative factors, including prolonged anesthesia time, surgical procedures requiring > 90 
minutes for completion, use of certain anesthetic drugs, and hypothermia, can result in a greater 
risk of SSI, possibly because of increased bacterial contamination, excessive tissue manipulation, 
and dehydration.1,15,23,26 It has been suggested35 that substantial hemorrhage necessitating volume 
expansion, blood transfusion, and vasopressor or inotropic administration may dilute or increase 
the clearance of hydrophilic compounds (including cephalosporins), which thereby decreases 
concentration of the drug.35  
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Data for the present study supported clinical use such that a regimen of a total dose of 44 
mg of cefazolin/kg (22 mg/kg, IV, and 22 mg/kg, IM) administered 30 to 60 minutes before 
surgical procedures expected to last ≤ 4 hours and a single injection of cefazolin (22 mg/kg, IV) 
administered 30 to 60 before surgical procedures expected to last ≤ 3 hours should provide 
protection against the most common contaminants on the skin of dogs and cats (S 
pseudintermedius and Streptococcus spp). However, if E coli or other gram-negative bacteria are 
suspected, another antimicrobial and dosing regimen should be considered. Further studies are 
needed to validate these results in clinical settings and to assess interstitial fluid 
pharmacokinetics of cefazolin in anesthetized patients undergoing surgery. 
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 Figures 
 
Figure 1 - Semipermeable ultrafiltration probe threaded from cranial to caudal into the 
introducer needle to be placed subcutaneously. 
  
24 
 
Figure 2 - Mean cefazolin concentration-time curve for concentrations in interstitial fluid after 
administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group [circles]) and simultaneous 
IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group 
[squares]). Notice the MIC90 for Streptococcus spp (4 g/mL [dashed line]) and the MIC90 for 
Staphylococcus pseudintermedius (2 g/mL [dotted line]). 
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Figure 3 - Cefazolin concentration-time curves of the mean (squares), minimum (circles), and 
maximum (triangles) concentrations in interstitial fluid after administration of a single dose (22 
mg/kg, IV) to 5 dogs (IV group [A]). Notice the MIC90 for Streptococcus spp (4 g/mL [dashed 
line]) and the MIC90 for Staphylococcus pseudintermedius (2 g/mL [dotted line]). 
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Figure 4 - Cefazolin concentration-time curves of the mean (squares), minimum (circles), and 
maximum (triangles) concentrations in interstitial fluid after administration of a simultaneous IV 
and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group [B]). Notice 
the MIC90 for Streptococcus spp (4 g/mL [dashed line]) and the MIC90 for Staphylococcus 
pseudintermedius (2 g/mL [dotted line]). 
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 Tables 
Table 1 - Mean, minimum, and maximum concentrations of cefazolin (g/kg) in interstitial fluid 
after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group) and simultaneous IV 
and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group). 
  IV group    IV + IM group    
Time (h) Mean Minimum Maximum Mean Minimum Maximum P value* 
1 39.6 16.0  66.5  38.3 19.2  56.6  0.924 
1.5 29.1 22.9  38.2  53.3 22.5  83.9  0.054 
2 21.2 11.8  26.2  46.4 39.8  51.2  0.001 
3 10.3 6.3  14.3  31.7 20.4  47.5  0.002 
4 6.4 4.0  9.9  19.1 9.7  41.4  0.042 
5 2.7 1.4  6.1  8.9 5.1  13.2  0.003 
*Comparison of mean values between groups; results were significant at P < 0.05. 
 
 
Table 2 - Pharmacokinetics of cefazolin after administration of a single dose (22 mg/kg, IV) to 5 
dogs (IV group) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) 
to 6 dogs (IV + IM group). 
 IV group     IV + IM group    
Parameter Mean Minimum Maximum Mean Minimum Maximum P value* 
AUCINF (h•g/mL) 74.99 49.60  97.01  154.16 115.14  223.24  0.004 
Cmax (g/mL) 37.3 22.9  66.5  51.5 26.4  83.9  0.177 
t1/2 (h)  0.96 0.63  1.28  1.11 0.84  1.52  0.429 
Tmax (h)  1.28 1.00  1.50  1.65 1.00  3.00  0.247 
*Comparison of mean values between groups; results were significant at P < 0.05. 
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 Footnotes 
a. Dexdomitor, Zoetis, Florham Park, NJ. 
b. Model MF-7023, BASi, West Lafayette, Ind. 
c. 2% lidocaine hydrochloride, Hospira Inc, Lake Forest, Ill. 
d. Ethilon 3-0, Ethicon, Somerville, NJ 
e. Model MD-1320, BASi, West Lafayette, Ind. 
f. Antisedan, Zoetis, Florham Park, NJ. 
g. Microsoft Office Excel 2011, Microsoft Corp, Redmond, Wash. 
h. Cefazolin, Westward Pharmaceutical, Eatontown, NJ. 
i. Fisher Scientific, Pittsburgh, Pa. 
j. BD, Franklin Lakes, NJ. 
k. Acquity UPLC, Waters Corp, Milford, Mass. 
l. 50 X 2.1 mm, 2.7 m pore size, Cortecs, Waters Corp, Milford Mass.   
m. WINKS SDA 6, version 6.0.93, Texasoft Inc, Cedar Hill, Tex. 
n. Phoenix 64, Certara, Princeton, NJ. 
o. Sigma Plot 12.5, Systat Software, Chicago, Ill. 
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Appendix A - BASi® Ultrafiltration Probe Image 
 
Figure A.1 UF-3-12 ultrafiltration sampling probe used in this study, with 29-μL volume 
capacity. 
